GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Affluent Medical (XPAR:AFME) » Definitions » Debt-to-Revenue

Affluent Medical (XPAR:AFME) Debt-to-Revenue : N/A (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Affluent Medical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Affluent Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €2.70 Mil. Affluent Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €14.26 Mil. Affluent Medical's annualized Revenue for the quarter that ended in Jun. 2024 was €0.00 Mil.


Affluent Medical Debt-to-Revenue Historical Data

The historical data trend for Affluent Medical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affluent Medical Debt-to-Revenue Chart

Affluent Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Affluent Medical Semi-Annual Data
Dec16 Dec17 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Affluent Medical's Debt-to-Revenue

For the Medical Devices subindustry, Affluent Medical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affluent Medical's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Affluent Medical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Affluent Medical's Debt-to-Revenue falls into.



Affluent Medical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Affluent Medical's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.778 + 15.057) / N/A
=N/A

Affluent Medical's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.697 + 14.26) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Affluent Medical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Affluent Medical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Affluent Medical Business Description

Traded in Other Exchanges
Address
320, Avenue Archimede, Les Pleiades III, Batiment B, Aix-en-Provence, FRA, 13100
Affluent Medical is a medical device company. The company is developing, next-generation minimally invasive medical devices for the treatment of severe pathologies in urology and structural heart. The product portfolio of the company includes Artus, Kalios, Epygon, and Kardiozis. It has a single operating segment that conducts research and development of medical devices with a view to its future marketing.

Affluent Medical Headlines

No Headlines